Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Core Insights - Alterity Therapeutics announced promising new data for ATH434 at the Society for Neuroscience 2024, highlighting its potential in treating neurodegenerative diseases [1][3] - ATH434 demonstrates potent antioxidant and mitochondrial-protectant effects, reducing lipid damage in neuronal injury models [2][3] - The study indicates ATH434's ability to promote energy production in mitochondria and protect against oxidative stress, which is crucial for neurodegenerative disease treatment [3][4] Company Overview - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, with ATH434 as its lead candidate [1][5] - ATH434 is designed to inhibit the aggregation of pathological proteins and has shown preclinical efficacy in reducing α-synuclein pathology [4][5] - The company is conducting two Phase 2 clinical trials for ATH434, targeting early-stage and advanced Multiple System Atrophy (MSA) [4][5] Research Findings - The study led by Dr. Daniel J. Kosman demonstrated ATH434's antioxidant properties and its role in cellular energy usage [2][3] - ATH434's mechanisms include reducing oxidative stress and redistributing excess labile iron, which may slow disease progression [3][4] - The research utilized menadione and hemin-induced models to assess ATH434's efficacy as a lipid peroxidation protectant [3][4]